Nerve Sheath Neoplasms: Clinical Trials

84 trials for Nerve Sheath Neoplasms, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

37 completed, 18 recruiting, 12 active not recruiting, 8 terminated. 84 Phase 1, 32 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 184Completed 37, Recruiting 18, Active not recruiting 12, Terminated 8, Not yet recruiting 3, Enrolling by invitation 2, Unknown 2, Suspended 1, Withdrawn 1
Phase 232Recruiting 9, Completed 7, Active not recruiting 6, Terminated 5, Not yet recruiting 3, Enrolling by invitation 1, Unknown 1

Follow Nerve Sheath Neoplasms: new trials by email Literature Review of Nerve Sheath Neoplasms trials Research Report on Nerve Sheath Neoplasms

Trials (filtered) newest first · largest first

All 84 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Safety and Efficacy of BMS-986504 in Unresectable Malignant Peripheral Nerve Sheath Tumor
BMS-986504 - Malignant Peripheral Nerve Sheath Tumors, MPNST
Phase 1 / Phase 2RecruitingAnkit Mangla, MD172026-08-012026-08-11
Luvometinib in Combination With Serplulimab for NF2-Related Tumors
Luvometinib, Serplulimab - NF2-related Schwannomatosis, NF2
Phase 1 / Phase 2Not yet recruitingBeijing Tiantan Hospital302026-07-312026-07-16
Study to Determine Optimal Dose, Evaluate the Efficacy and Safety of PRG-N-01 in Patients With Neurofibromatosis Type II
Trineumin - Neurofibromatosis Type II, NF2
Phase 1 / Phase 2Not yet recruitingPRG Science & Technology Co., Ltd.252026-07-012026-01-23
Imaging Study of [89Zr]DFO-YS5 for Cancer Detection
[89Zr]DFO-YS5, Positron Emission Tomography (PET)-Computerized tomography (CT) - Bladder Cancer, Nerve Sheath Tumor
Phase 1RecruitingRobert Flavell, MD, PhD402026-06-152026-10-01
Study of Cabozantinib With Selumetinib for Plexiform Neurofibromas
Cabozantinib Oral Tablet, Selumetinib Oral Capsule - Neurofibromatosis 1, Plexiform Neurofibroma
Phase 1RecruitingGirish Dhall, MD302026-06-092026-10-02
Early Phase Study Evaluating MEK and MDM2 Inhibition in Patients With NF1 and MPNST
APG-115, Selumetinib - Malignant Peripheral Nerve Sheath Tumor (MPNST), Neurofibromatosis 1 (NF1)
Phase 1 / Phase 2RecruitingAeRang Kim452026-06-012026-07-27
Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors
Miltenyi CliniMACS Prodigy ® system, Zoledronic acid - Neuroblastoma, Rhabdomyosarcoma
Phase 1 / Phase 2RecruitingUniversity of Florida272026-02-112026-06-30
Feasibility and Tolerability of IMLYGIC for the Treatment of Cutaneous Neurofibromas in Adults With NF1
Imlygic - NF1, Neurofibromatosis
Phase 1RecruitingJohns Hopkins University102026-02-012026-05-08
A Study of DEG6498 in Participants With Solid Tumors
DEG6498 - Malignant Neoplasms
Phase 1RecruitingDegron Therapeutics Co.1002025-11-132026-06-30
Follow-up Study to Evaluate the Safety and Efficacy of FCN-159 in Pediatric Participants With Neurofibromatosis Type 1
Luvometinib Tablets - Neurofibromatosis 1, Plexiform Neurofibroma
Phase 1 / Phase 2Not yet recruitingShanghai Fosun Pharmaceutical Industrial Development Co. Ltd.652025-06-122025-06-17
PAS-004 in Adults Who Have Neurofibromatosis Type 1 With Plexiform Neurofibromas
PAS-004 Tablets, PAS-004 Capsule - NF1 Mutation, Neurofibroma Plexiform
Phase 1RecruitingPasithea Therapeutics Corp.562025-05-302026-10-28
Using CICS-1 and SPM-011 and [18F]FBPA Commissioned by CICS and Sumitomo Heavy Industries and STELLA PHARMA
BNCT, [18F]FBPA - Thoracic Solid Malignant Tumor
Phase 1 / Phase 2Enrolling by invitationStella Pharma Corporation302025-04-102025-11-19
Assessing the Efficacy of Repeat, Monthly Treatments of Deoxycholate for NF1 Associated Cutaneous Neurofibromas (cNFs)
Kybella - Neurofibromas, Cutaneous, Neurofibromatosis 1
Phase 1Enrolling by invitationMassachusetts General Hospital152025-04-082026-04-22
Anti-VEGF Gene Therapy Trial for Vestibular Schwannoma
AAVAnc80-antiVEGF via Akouos Delivery Device - Vestibular Schwannoma
Phase 1 / Phase 2RecruitingEli Lilly and Company272025-01-172026-11-04
A Phase I/II Study of Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocytic Leukemia
Trametinib, Azacitidine, Fludarabine - Leukemia, Juvenile Myelomonocytic, JMML
Phase 1 / Phase 2RecruitingTherapeutic Advances in Childhood Leukemia Consortium582024-10-112026-09-04
NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)
Surgical resection, Proton beam radiation therapy, Pazopanib - Adipocytic Neoplasm, Liposarcoma
Phase 1 / Phase 2RecruitingSt. Jude Children's Research Hospital1392024-03-272026-08-03
Efficacy of Skin Cooling in Reducing Pain Associated With Non-invasive Treatments of Neurofibromatosis Type 1 Cutaneous Neurofibromas
Deoxycholic Acid, Polidocanol, 1064nm Nd:YAG laser - Neurofibromatosis 1
Phase 1CompletedMassachusetts General Hospital132024-03-012025-11-21
A Study of Avutometinib for People With Solid Tumor Cancers
Avutometinib - Refractory Cancer, CNS Tumors
Phase 1CompletedMemorial Sloan Kettering Cancer Center32023-10-202026-11-04
SPEARHEAD-3 Pediatric Study
Afamitresgene autoleucel - Synovial Sarcoma, Malignant Peripheral Nerve Sheath Tumor (MPNST)
Phase 1 / Phase 2RecruitingUSWM CT, LLC202023-09-012026-08-11
Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors
TNG462, Pembrolizumab - Locally Advanced Solid Tumor
Phase 1 / Phase 2RecruitingTango Therapeutics, Inc.2252023-05-262026-09-08

Showing 20 of 84. Sign in to see all of them.

Narrower conditions

Neurofibrosarcoma (35)  ·  Neurofibromatosis 1 (30)  ·  Sarcoma (25)  ·  Sarcoma, Synovial (16)  ·  Rhabdomyosarcoma (13)  ·  Leiomyosarcoma (12)  ·  Neurofibroma, Plexiform (12)  ·  Histiocytoma, Malignant Fibrous (11)  ·  Liposarcoma (10)  ·  Osteosarcoma (10)  ·  Neuroblastoma (9)  ·  Neurofibromatoses (9)  ·  Sarcoma, Ewing (9)  ·  Fibrosarcoma (8)  ·  Hemangiosarcoma (7)

Broader conditions

Neoplasms by Histologic Type (84)  ·  Neoplasms, Nerve Tissue (84)  ·  Nervous System Diseases (83)  ·  Neoplasms (78)  ·  Neuromuscular Diseases (72)  ·  Peripheral Nervous System Diseases (72)  ·  Neurofibroma (71)  ·  Nervous System Neoplasms (62)  ·  Peripheral Nervous System Neoplasms (62)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (49)  ·  Genetic Diseases, Inborn (47)  ·  Neoplastic Syndromes, Hereditary (47)  ·  Heredodegenerative Disorders, Nervous System (41)  ·  Neurocutaneous Syndromes (41)

Interventions

AZD 6244 (9)  ·  Deoxycholic Acid (4)  ·  Sirolimus (4)  ·  Doxorubicin (3)  ·  Magnetic Resonance Spectroscopy (3)  ·  pazopanib (3)  ·  pembrolizumab (3)  ·  selinexor (3)  ·  2,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide (2)  ·  Bevacizumab (2)  ·  Cetuximab (2)  ·  Ifosfamide (2)  ·  Imatinib Mesylate (2)  ·  Lasers, Solid-State (2)  ·  Nivolumab (2)

Sponsors

National Cancer Institute (NCI) (14)  ·  AstraZeneca (5)  ·  Massachusetts General Hospital (5)  ·  Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (3)  ·  Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (2)  ·  European Organisation for Research and Treatment of Cancer - EORTC (2)  ·  Memorial Sloan Kettering Cancer Center (2)  ·  Seattle Children's Hospital (2)  ·  Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. (2)  ·  St. Jude Children's Research Hospital (2)  ·  Tango Therapeutics, Inc. (2)  ·  AeRang Kim (1)  ·  Ankit Mangla, MD (1)  ·  Ascentage Pharma Group Inc. (1)  ·  Beijing Tiantan Hospital (1)

Countries

United States (69)  ·  China (7)  ·  France (4)  ·  Spain (4)  ·  Australia (3)  ·  Canada (3)  ·  Japan (3)  ·  Russia (3)  ·  United Kingdom (3)  ·  Denmark (2)  ·  Germany (2)  ·  Netherlands (2)  ·  Austria (1)  ·  Belgium (1)  ·  Italy (1)

Top investigators

Brigitte C Widemann, M.D. (4)  ·  Richard R Anderson, MD (3)  ·  AeRang Kim, MD, PhD (2)  ·  Jason R Fangusaro (2)  ·  Aaron H. Wolfson, MD (1)  ·  Aaron Tward, MD (1)  ·  Albiruni Razak, M.D. (1)  ·  Ankit Mangla, MD (1)  ·  Antonio Omuro (1)  ·  Brigitte C. Widemann, MD (1)  ·  Brigitte Widemann, MD (1)  ·  Carlos Romo, MD (1)  ·  Carrie E Bearden, PhD (1)

Results publications

PMID 11705489, PMID 12528778, PMID 12957454, PMID 15010069, PMID 15592836, PMID 19088049, PMID 21764821, PMID 22934754, PMID 23382028, PMID 25858498, PMID 26933802, PMID 28029918, PMID 30410720, PMID 31151904, PMID 31401903, PMID 32089640, PMID 32187457, PMID 33470897, PMID 33641042, PMID 34321280, PMID 34331515, PMID 35170228, PMID 35410754, PMID 35467749, PMID 36375115, PMID 36884302, PMID 37115514, PMID 37311055, PMID 37400844, PMID 38721358, PMID 38869947, PMID 39255444, PMID 39756156, PMID 40709016, PMID 41139346, PMID 41389341, PMID 41592259, PMID 42394972, PMID 42540436

NIH funding

P30CA008748 (2), U01CA069856 (2), UM1CA081457 (2), K08CA245181 (1), N01CM00071 (1), N01CM62206 (1), P30CA014599 (1), P50CA103175 (1), U01CA081457 (1), U10CA180821 (1)